Abstract:Abstract This retrospective study, using UK Clinical Practice Research Datalink and Hospital Episode Statistics databases, analysed 17,239 incident patients with vitiligo. Mean incidence of vitiligo was 0.16 (2010–2021) per 1000 person-years (range: 0.10 [2010-COVID] to 0.19 [2013/2018]); prevalence increased from 0.21% (2010) to 0.38% (2021). The most common comorbidities recorded after vitiligo diagnosis were diabetes (19.4%), eczema (8.9%), thyroid disease (7.5%), and rheumatoid arthritis (6.9%). Mental health diagnoses recorded at any time were most commonly depression and/or anxiety (24.6%), depression (18.5%), anxiety (16.0%), and sleep disturbance (12.7%); recorded after vitiligo diagnosis in 6.4%, 4.4%, 5.5%, and 3.9%, respectively. Mental health comorbidities were more common among White patients (eg, depression and/or anxiety, 29.0%) than Black (18.8%), Asian (16.1%), and other ethnicities (21.4%). In adolescents, depression and/or anxiety was most commonly diagnosed after vitiligo diagnosis (7.4% vs before, 1.8%). Healthcare resources were used most frequently in the first year after vitiligo diagnosis (incident cohort), typically dermatology-related outpatient appointments (101.9/100 person-years) and general practitioner consultations (97.9/100 person-years). In the year after diagnosis, 60.8% of incident patients did not receive vitiligo-related treatments (ie, topical corticosteroids, topical calcineurin inhibitors, oral corticosteroids, phototherapy), increasing to 82.0% the next year; median (95% CI) time from diagnosis to first treatment was 34.0 (31.6–36.4) months. Antidepressants and/or anxiolytics were recorded for 16.7% of incident patients in the year after diagnosis. In 2019, 85.0% of prevalent patients did not receive vitiligo-related treatments; 16.6% had a record of antidepressant and/or anxiolytic treatments. Most patients were not on vitiligo-related treatments within a year of diagnosis, with time to first treatment >2 years, suggesting that vitiligo may be dismissed as unimportant and not treated early, in part due to limited effectiveness of available treatments. New effective treatments, early initiation, and psychological intervention and support are needed to reduce vitiligo burden on patients.

A Study on Drug Prescribing Patterns in Vitiligo Patients of Andhra Pradesh in a Tertiary Care Teaching Hospital

Implication of colloidal therapeutics in the treatment of vitiligo: Portray of signaling cascade, current drug-targets and preclinical and clinical evidences

Emerging therapies and innovations in vitiligo management: a comprehensive review

Burden of Disease and Treatment Patterns Amongst Patients With Vitiligo: Findings From a National, Longitudinal Retrospective Study in the United Kingdom

Vitiligo and Surgical interventions in its treatment

Epidemiology and Treatment Patterns of Patients with Vitiligo: A Real-World Analysis

Understanding Vitiligo: Causes, Diagnosis, Promising Advances in Treatment and Management and the Impact on Mental Health

Vitiligo outpatient management in the United States: findings from the 2012–2019 National Ambulatory Medical care Survey (NAMCS)

Up-and-Coming Drugs for the Treatment of Vitiligo

Proportion Of vitiligo and associated factors among patients visiting dermatology opd in tibebe ghion specialized hospital and addisalem primary hospital, bahirdar city, Ethiopia,2023

Emerging drugs for the treatment of vitiligo

Clinico-epidemiological profile of childhood vitiligo: Experience from a tertiary care center of Northeast India

Evaluation of Serum Levels of Vitamin D in Patients with Vitiligo: A Case-Control Study

Exploring the impact of diet and nutrition on vitiligo: A systematic review of dietary factors and nutritional interventions

A Holistic Review on the Autoimmune Disease Vitiligo with Emphasis on the Causal Factors

A systematic review of case series and clinical trials investigating systemic oral or injectable therapies for the treatment of vitiligo

Using a Topical Formulation of Vitamin D for the Treatment of Vitiligo: A Systematic Review

Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy

Real-World Experience of Vitiligo Patients: A Retrospective Chart Review

Effect of Topical 5% 5-Fluorouracil with Microneedling in Vitiligo Patients as an Additional Modality to Standard Treatment at Tertiary Care Hospital

Dietary habits in adult Japanese patients with vitiligo